204 related articles for article (PubMed ID: 11941264)
1. Ertapenem (Invanz)--a new parenteral carbapenem.
Med Lett Drugs Ther; 2002 Mar; 44(1126):25-6. PubMed ID: 11941264
[No Abstract] [Full Text] [Related]
2. Ertapenem.
Parakh A; Krishnamurthy S; Bhattacharya M
Kathmandu Univ Med J (KUMJ); 2009; 7(28):454-60. PubMed ID: 20502094
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
Nix DE; Majumdar AK; DiNubile MJ
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii23-8. PubMed ID: 15150180
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
5. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
Wells WG; Woods GL; Jiang Q; Gesser RM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
[TBL] [Abstract][Full Text] [Related]
7. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
Teng CP; Chen HH; Chan J; Lye DC
Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
[TBL] [Abstract][Full Text] [Related]
8. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
Hammond ML
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii7-9. PubMed ID: 15150178
[TBL] [Abstract][Full Text] [Related]
9. Parenteral carbapenems.
Shah PM
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
[TBL] [Abstract][Full Text] [Related]
10. Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects.
Cunha BA
Drugs Today (Barc); 2002 Mar; 38(3):195-213. PubMed ID: 12532175
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Vetter N; Cambronero-Hernandez E; Rohlf J; Simon S; Carides A; Oliveria T; Isaacs R;
Clin Ther; 2002 Nov; 24(11):1770-85. PubMed ID: 12501873
[TBL] [Abstract][Full Text] [Related]
12. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.
Tice AD
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii83-6. PubMed ID: 15150187
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem.
Congeni BL
Expert Opin Pharmacother; 2010 Mar; 11(4):669-72. PubMed ID: 20163277
[TBL] [Abstract][Full Text] [Related]
14. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
[TBL] [Abstract][Full Text] [Related]
15. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
Goldstein EJ; Snydman DR
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
[TBL] [Abstract][Full Text] [Related]
16. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.
Burkhardt O; Derendorf H; Welte T
Expert Opin Pharmacother; 2007 Feb; 8(2):237-56. PubMed ID: 17257093
[TBL] [Abstract][Full Text] [Related]
17. Doripenem (Doribax)--a new parenteral carbapenem.
Med Lett Drugs Ther; 2008 Jan; 50(1278):5-7. PubMed ID: 18219262
[No Abstract] [Full Text] [Related]
18. [Initial treatment can lighten low-severity community-acquired pneumonia].
Wasielewski S
Med Monatsschr Pharm; 2005 Nov; 28(11):413. PubMed ID: 16309029
[No Abstract] [Full Text] [Related]
19. Prolonged β-lactam infusion for Gram-negative Infections.
Tamma PD; Jenh AM; Milstone AM
Pediatr Infect Dis J; 2011 Apr; 30(4):336-7. PubMed ID: 21407037
[No Abstract] [Full Text] [Related]
20. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Gesser RM; McCarroll K; Teppler H; Woods GL
J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
